Literature DB >> 838847

Effect of dopamine on plasma growth hormone and prolactin levels in normal and acromegalic subjects.

F Camanni, F Massara, L Belforte, A Rosatello, G M Molinatti.   

Abstract

In contrast with other dopaminergic drugs (L-dopa, apomorphine or bromocriptine) a 280 mug/min dose of dopamine infused for 120 min failed to induce an increase in plasma GH in 9 normal subjects. During dopamine infusion, no significant change in the GH response to arginine was also noted, whereas prolactin displayed a significant fall. In 15 acromegalic patients, on the other hand, the drug caused a marked fall in both GH (mean+/-SE; 71.1%+/-5.6) and prolactin (mean+/-SE; 67.6%+/-4.0) followed by a distinct rebound after the end of the test. There was a very close relation (P less than 0.001) between the maximum per cent decrease in GH during dopamine and after 2.5 mg bromocriptine by mouth. Dopamine also inhibited the GH response to TRH (4 patients). Since dopamine does not readily cross the blood-brain barrier, these results suggest that the stimulating effect of dopaminergic drugs on GH secretion in the normal subject is exerted via the CNS, whereas in acromegaly there is a direct action on structures lying outside the blood-brain barrier, probably in the hypophysis. Dopaminergic inhibition of prolactin is primarily the result of action on the hypophysis, as well as on the hypothalamus, in both normal and acromegalic subjects.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 838847     DOI: 10.1210/jcem-44-3-465

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

Review 1.  Some current aspects of clinical and experimental neuroendocrinology with particular reference to growth hormone, thyrotropin and prolactin.

Authors:  M F Scanlon; M Pourmand; A M McGregor; M D Rodriguez-Arnao; K Hall; A Gomez-Pan; R Hall
Journal:  J Endocrinol Invest       Date:  1979 Jul-Sep       Impact factor: 4.256

Review 2.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

Review 3.  Drug-induced changes in prolactin secretion. Clinical implications.

Authors:  K Hell; H Wernze
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Nov-Dec

4.  Dopamine during alpha- or beta-adrenergic blockade in man. Hormonal, metabolic, and cardiovascular effects.

Authors:  M Lorenzi; J H Karam; E Tsalikian; N V Bohannon; J E Gerich; P H Forsham
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

5.  Dopamine blockade of the thyroliberin -- induced cyclic AMP accumulation in rat anterior pituitary.

Authors:  M Pawlikowski; E Karasek; J Kunert-Radek; H Stepień
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

6.  Inhibition of thyrotropin and prolactin secretion by dopamine in man.

Authors:  F Massara; F Camanni; V Vergano; L Belforte; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

7.  COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.

Authors:  T Keränen; A Gordin; M Koulu; M Scheinin; S Antila; S Sundberg; T Wikberg
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 8.  Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.

Authors:  E E Müller; M Rolla; E Ghigo; D Belliti; E Arvat; A Andreoni; A Torsello; V Locatelli; F Camanni
Journal:  Drugs       Date:  1995-11       Impact factor: 9.546

9.  Increased growth hormone response to dopamine infusion in insulin-dependent diabetic subjects: indication of possible blood-brain barrier abnormality.

Authors:  M Lorenzi; J H Karam; M B McIlroy; P H Forsham
Journal:  J Clin Invest       Date:  1980-01       Impact factor: 14.808

10.  Effect of domperidone on apomorphine-induced growth hormone secretion in normal men.

Authors:  S Lal; N P Nair; H L Iskandar; P Etienne; P L Wood; G Schwartz; H Guyda
Journal:  J Neural Transm       Date:  1982       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.